LABS.JK PT UBC Medical Indonesia Tbk
- Market cap
- IDR 498B
- P/E
- -
- P/B
- -
- ROE
- 5.4%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LABS.JK undervalued?
Graham numberThe Graham number of PT UBC Medical Indonesia Tbk cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PT UBC Medical Indonesia Tbk fundamental analysis
8 of 22 checks passedROE 0/2
Low return on equity (5.4%), below 10%.
ROA 1/1
Return on assets (3.8%) is above the industry median (-7.4%).
Profit Consistency 2/2
Profitable for 5 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (206.0%) is above the industry median (5.2%).
Revenue Growth 2/2
Revenue grew 28.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (15.2%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 11.4x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book is negative or not available.
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
PT UBC Medical Indonesia Tbk stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PT UBC Medical Indonesia Tbk
PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables; and Diagnostics and Equipment. The company offers NeoMoDX molecular system; Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT; Airdoc Retina AI, a screening technology that uses Artificial Intelligence (AI) to detect chronic diseases such as diabetic retinopathy and hypertension; Hisky; and All-in-one GP workstation. It also provid…
Full company profilePT UBC Medical Indonesia Tbk financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PT UBC Medical Indonesia Tbk annual financial statements
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 130B | 93.3B | 137B | 148B | 199B | 190B |
| Gross Profit | 53.1B | 30.3B | 46.5B | 45.6B | 67.5B | 66.6B |
| Operating Income | 3.19B | 3.40B | 5.84B | 8.95B | 20.4B | 14.5B |
| EBITDA | 10.6B | 14.9B | 17.9B | 22.0B | 32.9B | 27.7B |
| Net Income | 308M | 2.83B | 2.19B | 2.95B | 13.5B | 8.48B |
| EPS | 0.08 | 0.72 | 0.55 | 0.75 | 2.29 | 2.15 |
| Balance Sheet | ||||||
| Total Assets | 95.0B | 109B | 160B | 204B | 228B | 223B |
| Total Liabilities | 85.8B | 61.3B | 111B | 64.8B | 75.7B | 66.6B |
| Shareholders' Equity | 9.23B | 47.5B | 49.4B | 139B | 152B | 157B |
| Cash & Short-term Investments | 11.6B | 828M | 3.62B | 42.6B | 41.2B | 6.86B |
| Total Debt | 31.2B | 19.9B | 41.4B | 35.9B | 27.5B | 23.8B |
| Cash Flow | ||||||
| Operating Cash Flow | -20.6B | -15.0B | -14.8B | -13.7B | 22.9B | -52.6B |
| Capital Expenditure | 11.7B | 3.89B | 20.1B | 6.81B | 14.2B | 8.32B |
| Free Cash Flow | -32.3B | -18.9B | -34.9B | -20.5B | 8.68B | -60.9B |
| Ratios | ||||||
| ROE | 3.3% | 6.0% | 4.4% | 2.1% | 8.9% | 5.4% |
| ROA | 0.3% | 2.6% | 1.4% | 1.5% | 5.9% | 3.8% |
| Net Profit Margin | 0.2% | 3.0% | 1.6% | 2.0% | 6.8% | 4.5% |
| Debt to Equity | 3.38x | 0.42x | 0.84x | 0.26x | 0.18x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PT UBC Medical Indonesia Tbk dividends
PT UBC Medical Indonesia Tbk has not paid dividends in the last 5 fiscal years.
Who owns PT UBC Medical Indonesia Tbk
- Insiders 82.28%
- Institutions 0.00%
- Public & others 17.72%
- Shares outstanding 3.95B
- Free float 701M
PT UBC Medical Indonesia Tbk company profile
- Company name
- PT UBC Medical Indonesia Tbk
- Ticker
- LABS.JK
- Exchange
- Jakarta Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 54
- Fiscal year end
- December
- Address
- Kawasan Industri Pulogadung, Jakarta Timur, Indonesia, 13930
- Phone
- 62 21 3886 5110
- Website
- ubcindonesia.com
About PT UBC Medical Indonesia Tbk
PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables; and Diagnostics and Equipment. The company offers NeoMoDX molecular system; Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT; Airdoc Retina AI, a screening technology that uses Artificial Intelligence (AI) to detect chronic diseases such as diabetic retinopathy and hypertension; Hisky; and All-in-one GP workstation. It also provides TB management products, such as Quantiferon TB Hold Plus, Genoscholar, and Ina TB; QIAstat-DX Analyzer; and newborn screening products, including GSP Neonatal and Delfia Neonatal Kit, Neonatal Sampling Paper, and Victor2 D; and Care HPV System and Hybrid Capture 2 - HPV DNA Test. In addition, the company engages in the wholesale of laboratory equipment, pharmaceutical equipment, and medical equipment for human beings and animals; and provision of chemical products and traditional medicine. It serves hospitals, clinical laboratories, and diagnostic centers, as well as central general hospitals, private hospitals, regional public hospitals, the ministry of health, and other ministries. The company was founded in 2014 and is based in Jakarta Timur, Indonesia. PT UBC Medical Indonesia Tbk is a subsidiary of PT Optel Investama Mulia.
PT UBC Medical Indonesia Tbk management
3- Mr. Franciscus Xaverius Yoshua RaintjungCorporate Secretary & President Director · born 1979
- Ms. Marcella AngelinDirector of Finance & Director · born 1987
- Muhammad Fajar ShodiqChief of Internal Audit Unit · born 1995